Histone deacetylase inhibitors and periodontal bone loss

Journal of Periodontal Research

Volumn 46, Issue 6, 2011, Pages 697-703

  Cantley, M D ^a   Bartold, P M ^a   Marino, V ^a   Fairlie, D P ^b   Le, G T ^b   Lucke, A J ^b   Haynes, D R ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Bone resorption; Histone deacetylase inhibitor; Osteoclasts; Periodontitis

Indexed keywords

AMINOQUINOLINE DERIVATIVE; BENZAMIDE DERIVATIVE; ENTINOSTAT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; N8 HYDROXY 2 (1H INDOLE 2 CARBOXAMIDO) N1 (QUINOLIN 8 YL)OCTANEDIAMIDE; N8-HYDROXY-2-(1H-INDOLE-2-CARBOXAMIDO)-N1-(QUINOLIN-8-YL)OCTANEDIAMIDE; OLIVE OIL; PYRIDINE DERIVATIVE; VEGETABLE OIL;

ALVEOLAR BONE LOSS; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BONE DENSITY; ENZYMOLOGY; FEMALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; OSTEOCLAST; PATHOLOGY; PERIODONTITIS; PORPHYROMONAS GINGIVALIS; RADIOGRAPHY; THREE DIMENSIONAL IMAGING;

ALVEOLAR BONE LOSS; AMINOQUINOLINES; ANIMALS; BENZAMIDES; BONE DENSITY; FEMALE; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; IMAGING, THREE-DIMENSIONAL; MICE; MICE, INBRED BALB C; OSTEOCLASTS; PERIODONTITIS; PLANT OILS; PORPHYROMONAS GINGIVALIS; PYRIDINES; X-RAY MICROTOMOGRAPHY;

EID: 80054892294     PISSN: 00223484     EISSN: 16000765     Source Type: Journal    
DOI: 10.1111/j.1600-0765.2011.01392.x     Document Type: Article

References (39)

1. Bartold PM, Cantley MD, Haynes DR. Mechanisms and control of pathologic bone loss in periodontitis. Periodontol 2010;53:55-69.
2. Assuma R, Oates T, Cochran D, Amar S, Graves DT. IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. J Immunol 1998;160:403-409.
3. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 2001;79:243-253.
4. Mogi M, Otogoto J, Ota N, Togari A. Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. J Dent Res 2004;83:166-169.
5. Crotti T, Smith MD, Hirsch R et al. Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J Periodontal Res 2003;38:380-387.
6. Lu HK, Chen YL, Chang HC, Li CL, Kuo MY. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis. J Periodontal Res 2006;41:354-360.
7. Perrone M. FDA clears Amgen's bone-strengthening drug Prolia. Biosci Technol 2010. URL: [accessed on 3 June 2011].
8. Richon VM, O'Brien JP. Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. Clin Cancer Res 2002;8:662-664.
9. Chen LF, Greene WC. Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol 2004;5:392-401.
10. Trepel J, Birrer MJ. A link between histone deacetylase inhibitors and NF- kappaB signaling. Cell Cycle 2003;2:452-453.
11. Imre G, Gekeler V, Leja A, Beckers T, Boehm M. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation. Cancer Res 2006;66:5409-5418.
12. Chung YL, Lee MY, Wang AJ, Yao LF. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 2003;8:707-717.
13. Passoja A, Puijola I, Knuuttila M et al. Serum levels of interleukin-10 and tumour necrosis factor-alpha in chronic periodontitis. J Clin Periodontol 2010; 37: 881-887. Doi: Epub 02010 Aug 01617.
14. Nakamura T, Kukita T, Shobuike T et al. Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production. J Immunol 2005;175:5809-5816.
15. Rahman MM, Kukita A, Kukita T, Shobuike T, Nakamura T, Kohashi O. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood 2003;101:3451-3459.
16. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 2006;281:5612-5622.
17. Duncan HF, Smith AJ, Fleming GJ, Cooper PR. HDACi: cellular effects, opportunities for restorative dentistry. J Dent Res 2011;2:2.
18. Schroeder TM, Westendorf JJ. Histone deacetylase inhibitors promote osteoblast maturation. J Bone Miner Res 2005; 20: 2254-2263. Epub 2005 Aug 2258.
19. Lee HW, Suh JH, Kim AY, Lee YS, Park SY, Kim JB. Histone deacetylase 1-mediated histone modification regulates osteoblast differentiation. Mol Endocrinol 2006;20:2432-2443. Epub 2006 May 2425.
20. Cantley M, Fairlie D, Bartold P et al. Compounds that inhibit histone deacetylases in class I and class II effectively suppress human osteoclasts in vitro. J Cell Physiol 2011;22:22684.
21. Kim HN, Ha H, Lee JH et al. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL. Eur J Pharmacol 2009;623:22-29. Epub 2009 Sep 2017.
22. Lin HS, Hu CY, Chan HY et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 2007;150:862-872. Epub 2007 Feb 2026.
23. Nasu Y, Nishida K, Miyazawa S et al. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthritis Cartilage 2008;16:723-732. Epub 2008 Jan 2015.
24. Cantley MD, Bartold PM, Marino V et al. The use of live-animal micro-computed tomography to determine the effect of a novel phospholipase A2 inhibitor on alveolar bone loss in an in vivo mouse model of periodontitis. J Periodontal Res 2009;44:317-322.
25. Kahnberg P, Lucke AJ, Glenn MP et al. Design, synthesis, potency, and cytoselectivity of anticancer agents derived by parallel synthesis from alpha-aminosuberic acid. J Med Chem 2006;49:7611-7622.
26. Ryan QC, Headlee D, Acharya M et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005;23:3912-3922. Epub 2005 Apr 3925.
27. Cantley M, Haynes D, Marino V, Bartold P. Pre-existing periodontitis exacerbates rheumatoid arthritis in a mouse model. J Clin Periodontol 2011;38(6):532-541.
28. Bendyk A, Marino V, Zilm PS, Howe P, Bartold PM. Effect of dietary omega-3 polyunsaturated fatty acids on experimental periodontitis in the mouse. J Periodontal Res 2009;44:211-216. Epub 2009 Feb 2006.
29. Puel C, Quintin A, Agalias A et al. Olive oil and its main phenolic micronutrient (oleuropein) prevent inflammation-induced bone loss in the ovariectomised rat. Br J Nutr 2004;92:119-127.
30. Chiang CY, Kyritsis G, Graves DT, Amar S. Interleukin-1 and tumor necrosis factor activities partially account for calvarial bone resorption induced by local injection of lipopolysaccharide. Infect Immun 1999;67:4231-4236.
31. Li CH, Amar S. Morphometric, histomorphometric, and microcomputed tomographic analysis of periodontal inflammatory lesions in a murine model. J Periodontol 2007;78:1120-1128.
32. Gupta PK, Reid RC, Liu L et al. Inhibitors selective for HDAC6 in enzymes and cells. Bioorg Med Chem Lett 2010;20:7067-7070. Epub 2010 Oct 7012.
33. Hu E, Dul E, Sung CM et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 2003;307:720-728.
34. Horiuchi M, Morinobu A, Chin T, Sakai Y, Kurosaka M, Kumagai S. Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. J Rheumatol 2009;36:1580-1589. Epub 2009 Jun 1516.
35. Kawabata T, Nishida K, Takasugi K et al. Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis. Arthritis Res Ther 2010;12:R133.
36. Bartold PM, Marshall RI, Haynes DR. Periodontitis and rheumatoid arthritis: a review. J Periodontol 2005;76:2066-2074.
37. Bartold PM, Marino V, Cantley M, Haynes DR. Effect of Porphyromonas gingivalis-induced inflammation on the development of rheumatoid arthritis. J Clin Periodontol 2010;37:405-411.
38. Piekarz RL, Sackett DL, Bates SE. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy. Cancer J 2007;13:30-39.
39. Suzuki T, Ando T, Tsuchiya K et al. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem 1999;42:3001-3003.